Next 10 |
2024-07-05 15:18:48 ET Summary Caribou Biosciences, Inc. experienced a 45% share price decline after presenting puzzling results for their product candidate CB-010 in a Phase 1 clinical trial. CB-010 showed limited efficacy in treating relapsed/refractory non-Hodgkin's lymphoma, w...
2024-07-03 03:11:04 ET Summary Caribou Biosciences develops allogeneic therapies using CRISPR technology, focusing on hematologic cancers and autoimmune diseases. CB-010, CB-011, and CB-012 are in Phase 1 clinical trials, with CB-010 showing promising results for B cell non-Hodgki...
2024-06-04 08:30:04 ET H.C. Wainwright analyst issues BUY recommendation for CRBU on June 4, 2024 06:46AM ET. The previous analyst recommendation was Buy. CRBU was trading at $2.145 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ...
2024-06-03 10:02:56 ET More on Caribou Bioscience Caribou Biosciences: 2 Clinical Data Updates In 2024 Could Bring Value Caribou Biosciences GAAP EPS of -$0.46 misses by $0.05, revenue of $2.43M beats by $0.01M Caribou Biosciences received IND clearance from FDA for ...
A look at the top 10 most actives in the United States Crown Electrokinetics Corp. (CRKN) rose 22.3% to $0.12231 on volume of 147,748,197 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 11.8% to $0.6524 on volume of 95,235,738 shares AMC Entertainment Holdings Inc. Class A (AM...
-- CB-010 allogeneic CAR-T cell therapy w ith partial HLA matching has potential to rival efficacy and safety profile of approved autologous CAR-T cell therapies -- -- 14.4 months median PFS in ANTLER patients with partial HLA matching (≥4 alleles) -- -- Plan to...
BERKELEY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s participation in the following event and investor conferences: • Caribou...
2024-05-24 16:58:54 ET Gainers: Photronics ( PLAB ) +6% . Replimune Group ( REPL ) +4% . Caribou Biosciences ( CRBU ) +3% . Symbotic ( SYM ) +3% . Arhaus ( ARHS ) +3% . Losers: OneMedNet ( ONMD ) -...
2024-05-23 16:47:49 ET Gainers: Ross Stores ( ROST ) +6% . Frontier Group Holdings ( ULCC ) +4% . Caribou Biosciences ( CRBU ) +4% . Absci Corporation ( ABSI ) +3% . Protara Therapeutics ( TARA ) +3% . Losers: Domo ( DO...
2024-05-20 16:47:47 ET Gainers: Maravai LifeSciences ( MRVI ) +5% . Caribou Biosciences ( CRBU ) +4% . Greenidge Generation Holdings ( GREE ) +4% . Cipher Mining ( CIFR ) +4% . SIGA Technologies ( SIGA ) +4%...
News, Short Squeeze, Breakout and More Instantly...
Caribou Biosciences Inc. Company Name:
CRBU Stock Symbol:
NASDAQ Market:
Caribou Biosciences Inc. Website:
2024-06-04 08:30:04 ET H.C. Wainwright analyst issues BUY recommendation for CRBU on June 4, 2024 06:46AM ET. The previous analyst recommendation was Buy. CRBU was trading at $2.145 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ...
A look at the top 10 most actives in the United States Crown Electrokinetics Corp. (CRKN) rose 22.3% to $0.12231 on volume of 147,748,197 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 11.8% to $0.6524 on volume of 95,235,738 shares AMC Entertainment Holdings Inc. Class A (AM...
-- CB-010 allogeneic CAR-T cell therapy w ith partial HLA matching has potential to rival efficacy and safety profile of approved autologous CAR-T cell therapies -- -- 14.4 months median PFS in ANTLER patients with partial HLA matching (≥4 alleles) -- -- Plan to...